Given that ATM loss of function variants are estimated to be associated with only a modest risk of breast cancer (OR 3.0, 95% CI 2.1–4.5) [52], larger well-designed studies will be required to determine if ATM variation confers a similar modest level of risk to EC. This evidence concerns the gene ATM and breast cancer.